Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Aug 17;9(1):71.
doi: 10.1186/s13045-016-0301-2.

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Michael M B Green  1 , Nelson Chao  1 , Saurabh Chhabra  2 , Kelly Corbet  1 , Cristina Gasparetto  1 , Ari Horwitz  1 , Zhiguo Li  3 , Jagadish Kummetha Venkata  2 , Gwynn Long  1 , Alice Mims  4 , David Rizzieri  1 , Stefanie Sarantopoulos  1 , Robert Stuart  2 , Anthony D Sung  1 , Keith M Sullivan  1 , Luciano Costa  2 , Mitchell Horwitz  1 , Yubin Kang  5   6
Affiliations
Clinical Trial

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Michael M B Green et al. J Hematol Oncol. .

Abstract

Background: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducing HSC proliferation.

Methods: We conducted a phase I/II trial of plerixafor on hematopoietic cell recovery following myeloablative allogeneic HSCT. Patients with hematologic malignancies receiving myeloablative conditioning were enrolled. Plerixafor 240 μg/kg was administered subcutaneously every other day beginning day +2 until day +21 or until neutrophil recovery. The primary efficacy endpoints of the study were time to absolute neutrophil count >500/μl and platelet count >20,000/μl. The cumulative incidence of neutrophil and platelet engraftment of the study cohort was compared to that of a cohort of 95 allogeneic peripheral blood stem cell transplant recipients treated during the same period of time and who received similar conditioning and graft-versus-host disease prophylaxis.

Results: Thirty patients received plerixafor following peripheral blood stem cell (n = 28) (PBSC) or bone marrow (n = 2) transplantation. Adverse events attributable to plerixafor were mild and indistinguishable from effects of conditioning. The kinetics of neutrophil and platelet engraftment, as demonstrated by cumulative incidence, from the 28 study subjects receiving PBSC showed faster neutrophil (p = 0.04) and platelet recovery >20 K (p = 0.04) compared to the controls.

Conclusions: Our study demonstrated that plerixafor can be given safely following myeloablative HSCT. It provides proof of principle that blocking CXCR4 after HSCT enhances hematopoietic recovery. Larger, confirmatory studies in other settings are warranted.

Trial registration: ClinicalTrials.gov NCT01280955.

Keywords: Antagonist; CXCR4; Hematopoietic stem cell transplantation; Hematopoietic stem cells; Neutrophil engraftment; Outcomes; Platelet engraftment; Stromal-derived factor-1.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Scheme of the clinical study
Fig. 2
Fig. 2
Cumulative incidence of neutrophil engraftment and platelet engraftment. Left panel: cumulative incidence of neutrophil engraftment in plerixafor-treated patients (solid line) and control patients (dashed line). Right panel: cumulative incidence of platelet engraftment in plerixafor-treated patients (solid line) and contemporaneous control patients (dashed line). Excluding the two bone marrow recipients
Fig. 3
Fig. 3
Plasma cytokine levels measured at day 14 and day 30
Fig. 4
Fig. 4
Correlation analysis between the cytokine level at day 30 and the days of platelet engraftment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A, Rambaldi A, Bonifazi F, Bosi A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107. doi: 10.1186/s13045-015-0207-4. - DOI - PMC - PubMed
    1. Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P, Li QC, Zhang ZM, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG) J Hematol Oncol. 2014;7:59. doi: 10.1186/s13045-014-0059-3. - DOI - PMC - PubMed
    1. Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22:359–370. doi: 10.1016/j.bbmt.2015.09.013. - DOI - PMC - PubMed
    1. Bowie MB, McKnight KD, Kent DG, McCaffrey L, Hoodless PA, Eaves CJ. Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest. 2006;116:2808–2816. doi: 10.1172/JCI28310. - DOI - PMC - PubMed
    1. Cashman J, Clark-Lewis I, Eaves A, Eaves C. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood. 2002;99:792–799. doi: 10.1182/blood.V99.3.792. - DOI - PubMed

Publication types

MeSH terms

Associated data